Bayer AG

Product / Service

Bayer AG

Bayer receives FDA approval of Copanlisib in adults with relapsed follicular lymphoma after two prior systemic therapies; drug is administered intravenously

Bayer AG company details

The Bayer Group continued its successful development in the third quarter of 2011. On a currency- and portfolio-adjusted basis, sales rose by 4.8% to €8.7 billion (reported: +1.0%; Q3 2010: €8.6 billion), with the emerging markets accounting for a disproportionately large share of growth. The operating result (EBIT) advanced by a substantial 94.9% to €1.1 billion (Q3 2010: €0.6 billion)

| Tel: +49 214 30-1 |

Trending Topics

Approved Drugs/Devices
Blood Disorders
Branded Drugs
Drug Delivery/Ingestion
Drug/Device Reviews
Immune System Conditions

All content is copyrighted by Industry Intelligence, and the original respective author or source. You may not copy, recirculate, redistrubte or publish the content and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.